article · Advances in Biomarker Sciences and Technology
Faecal Microbial Transplantation (FMT), have been shown to be successfully managed along with a variety of gastrointestinal disorders, including Clostridioides difficile infection (CDI), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). FMT is a medical procedure that involves a donor transferring healthy gut bacteria to the recipient. The effectiveness of FMT is thought to be due to the ability of the healthy gut to restore balance to the recipient's microbiome, which is the community of microorganisms that inhabit the gastrointestinal tract. One of the key advantages of FMT is that it is a relatively simple and low-cost treatment option, compared to other therapies that may be more invasive or require long-term medication use. However, FMT is not without its limitations, including the potential for the transfer of infectious agents from the donor to the recipient and the potential for negative side effects in some patients. In this research, we discuss the current state of the evidence on FMT, including its potential benefits and risks, as well as future directions for research in this area.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.abst.2024.02.001
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.